PURPOSE: To investigate the expression profile of the hypoxia-inducible transcription factor-1α (HIF-1α) and its downstream targets in malignancies of the ocular adnexa and to determine its relevance as a prognostic factor for clinical outcome. METHODS: We included 49 subjects with malignant tumours (25 squamous cell carcinomas (SCC), 15 non-Hodgkin lymphomas, 9 melanomas) and 30 patients with benign tumours of the ocular adnexa (13 papillomas, 7 reactive lymphoid hyperplasias (RLHs) and 10 nevi) as controls. We quantified HIF-1α protein expression by immunohistochemistry and assessed the association between HIF-1α and clinical outcome via Kaplan-Meier analysis. Furthermore, we assessed the expression of HIF-1α downstream factors by transcriptional sequencing using the MACE (massive analysis of cDNA ends) technology. RESULTS: SCCs revealed a strong HIF-1α expression in 61% of tumour cells in comparison with only 22% in papillomas (p < 0.0001). In contrast, malignant melanomas and lymphomas revealed a similar HIF-1α expression compared with nevi and RLHs. Transcriptional sequencing and Gene Ontology Cluster analysis demonstrated 37 hypoxia-associated factors, including HIF-1α, VEGF, SFRP1 and LOXL2 that are significantly increased in SCC and may contribute to tumour proliferation, angiogenesis, and metastasis. Association analysis between HIF-1α immunoreactivity and clinical outcome revealed a trend towards an unfavourable prognosis in malignant tumours with increased HIF-1α expression. CONCLUSIONS: HIF-1α protein is increased in malignant tumours of the ocular adnexa, which is associated with an increase in multiple HIF-1α-downstream factors and a trend towards an unfavourable clinical outcome.
PURPOSE: To investigate the expression profile of the hypoxia-inducible transcription factor-1α (HIF-1α) and its downstream targets in malignancies of the ocular adnexa and to determine its relevance as a prognostic factor for clinical outcome. METHODS: We included 49 subjects with malignant tumours (25 squamous cell carcinomas (SCC), 15 non-Hodgkin lymphomas, 9 melanomas) and 30 patients with benign tumours of the ocular adnexa (13 papillomas, 7 reactive lymphoid hyperplasias (RLHs) and 10 nevi) as controls. We quantified HIF-1α protein expression by immunohistochemistry and assessed the association between HIF-1α and clinical outcome via Kaplan-Meier analysis. Furthermore, we assessed the expression of HIF-1α downstream factors by transcriptional sequencing using the MACE (massive analysis of cDNA ends) technology. RESULTS: SCCs revealed a strong HIF-1α expression in 61% of tumour cells in comparison with only 22% in papillomas (p < 0.0001). In contrast, malignant melanomas and lymphomas revealed a similar HIF-1α expression compared with nevi and RLHs. Transcriptional sequencing and Gene Ontology Cluster analysis demonstrated 37 hypoxia-associated factors, including HIF-1α, VEGF, SFRP1 and LOXL2 that are significantly increased in SCC and may contribute to tumour proliferation, angiogenesis, and metastasis. Association analysis between HIF-1α immunoreactivity and clinical outcome revealed a trend towards an unfavourable prognosis in malignant tumours with increased HIF-1α expression. CONCLUSIONS: HIF-1α protein is increased in malignant tumours of the ocular adnexa, which is associated with an increase in multiple HIF-1α-downstream factors and a trend towards an unfavourable clinical outcome.
Authors: Steffi Lehmann; Daniel P Stiehl; Michael Honer; Marco Dominietto; Ruth Keist; Ivana Kotevic; Kristin Wollenick; Simon Ametamey; Roland H Wenger; Markus Rudin Journal: Proc Natl Acad Sci U S A Date: 2009-07-31 Impact factor: 11.205
Authors: Freya M Mowat; Ulrich F O Luhmann; Alexander J Smith; Clemens Lange; Yanai Duran; Sarah Harten; Deepa Shukla; Patrick H Maxwell; Robin R Ali; James W B Bainbridge Journal: PLoS One Date: 2010-06-14 Impact factor: 3.240
Authors: Woondong Jeong; Annamaria Rapisarda; Sook Ryun Park; Robert J Kinders; Alice Chen; Giovanni Melillo; Baris Turkbey; Seth M Steinberg; Peter Choyke; James H Doroshow; Shivaani Kummar Journal: Cancer Chemother Pharmacol Date: 2013-11-30 Impact factor: 3.333
Authors: Thomas Fillies; Richard Werkmeister; Paul J van Diest; Burkhard Brandt; Ulrich Joos; Horst Buerger Journal: BMC Cancer Date: 2005-07-21 Impact factor: 4.430
Authors: Simone Nuessle; Daniel Soriano; Daniel Boehringer; Hans Mittelviefhaus; Clemens Lange; Thomas Reinhard; Lisa Atzrodt; Claudia Auw-Haedrich Journal: Graefes Arch Clin Exp Ophthalmol Date: 2020-05-26 Impact factor: 3.117
Authors: Julian Wolf; Rozina Ida Hajdu; Stefaniya Boneva; Anja Schlecht; Thabo Lapp; Katrin Wacker; Hansjürgen Agostini; Thomas Reinhard; Claudia Auw-Hädrich; Günther Schlunck; Clemens Lange Journal: Front Med (Lausanne) Date: 2022-01-31